Suono Bio said today that Fujifilm (TSE:4901) made an undisclosed investment in the company to support its next-gen technology intended for the rapid, formulation-independent administration of therapeutics.
The Cambridge, Mass.-based company, formed last year by researchers out of the Massachusetts Institute of Technology and Brigham & Women’s Hospital, is developing technology intended for the rapid local administration of therapeutics intended to treat serious diseases.
Suono Bio said that it has shown pre-clinical activity in a range of diseases and a “diverse set” of therapeutics, including genetic material.
“I am thrilled that we have the opportunity to forge a long and fruitful relationship with Fujifilm to advance the development of our core technology. Their investment is a critical validation of our platform,” founding CEO Dr. Carl Schoellhammer said in a press release.
“Fujifilm has deep technical expertise and offers the chance to accelerate our development by working closely with their scientists and engineers in the future,” Dr. Robert Langer, whose laboratory at the Massachusetts Institute of Technology developed the technology behind the company’s platform, said in a prepared statement.
